Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
18 hedge funds and large institutions have $6.84M invested in Talis Biomedical Corporation Common Stock in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 18 → 18 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1% less capital invested
Capital invested by funds: $6.93M → $6.84M (-$92.5K)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.9K |
| 2 |
Renaissance Technologies
New York
|
+$17.7K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$1.3K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$115 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$51.6K |
| 2 |
Morgan Stanley
New York
|
-$4.86K |
| 3 |
BlackRock
New York
|
-$3.9K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.63K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$966 |
TLIS Hedge Fund Activity: Q2 2024 in Review
18 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q2 2024, worth a combined $6.84M — down 1.3% from $6.93M a quarter earlier.
Fund positioning in TLIS was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 6 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $18.9K. The largest seller was Susquehanna International Group, cutting an estimated $51.6K.
- 18 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $6.84M of Talis Biomedical Corporation Common Stock stock for Q2 2024, down 1.3% quarter-over-quarter.
- 2 funds opened new Talis Biomedical Corporation Common Stock positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q2 2024 was Geode Capital Management, an estimated $18.9K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q2 2024 was Susquehanna International Group, an estimated $51.6K sold.
Based on aggregated 13F filings for Q2 2024.